Short Sellers Back Off Big Pharma

Photo of Chris Lange
By Chris Lange Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The short interest data have been released for the July 31 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be big upside.

The July 31 short interest data have been compared with the previous figures, and for most of the selected stocks, short interest decreased.

Pfizer Inc. (NYSE: PFE) saw its short interest retreat to 49.08 million shares from the previous 50.37 million. In February, short interest spiked incredibly, and since that time it has slowly backed off. The highest short interest reading on the year was 207.4 million. Shares of Pfizer closed Tuesday at $35.12, within a 52-week trading range of $27.51 to $36.46.

Merck & Co. Inc. (NYSE: MRK) saw short interest decrease to 28.37 million shares from 29.47 million in the previous period. The last few readings have been the highest in the past 52 weeks. Merck shares closed Tuesday at $57.76, in a 52-week trading range of $52.49 to $63.62.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) short interest rose to 9.27 million shares. The level for the previous settlement date was 6.32 million. Shares of Teva closed Tuesday at $69.60, in a 52-week range of $47.36 to $72.31.

Bristol-Myers Squibb Co. (NYSE: BMY) saw its short interest fall to 20.26 million shares from the previous reading of 24.80 million. The past few readings, including the current one, are among the lowest of the year. Bristol-Myers shares closed Tuesday at $62.66, within a 52-week range of $47.55 to $70.54.

AbbVie Inc. (NYSE: ABBV) short interest continued its big turn downward to 44.48 million shares from the previous level of 53.31 million. Short interest has backed way off its highest level year to date; the highest reading in the past 52-weeks was 111.88 million. Shares of AbbVie closed Tuesday at $68.25, in a 52-week trading range of $52.06 to $71.60.

ALSO READ: Short Sellers Run for Cover From Major Biotechs

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618